Ropes & Gray advised ImmunoGen, a leader in the field of antibody-drug conjugates for cancer treatment, in a research collaboration with Biosion USA, a global research & development biotechnology company, to create novel antibody-drug conjugates. The collaboration was announced on December 13. Financial terms were not disclosed.
In the joint research effort, Biosion will leverage its high-throughput endocytosis platform to generate highly selective antibodies to targets allocated by each company and ImmunoGen will provide their linker-payload technology to create novel ADCs.
The Ropes & Gray team was led by life sciences licensing partner Amanda Austin and IP transactions associate Sarah Smith.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
